World Lung 2023 – targeted therapy to the rescue in small-cell lung
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
No keeping the red light on for Sting
CuraDev and OncoNano move into phase 1, trying to avoid the negative precedent of other Sting agonist projects.
Tivdak success could make life even harder for Iovance
Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.
Despite the setbacks, interest in TGF-β remains
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.
Royalty Pharma comes to Adstiladrin’s rescue
A royalty financing deal should see this gene therapy launched nine months after its surprise US approval.
Exelixis claims a label-expanding Cabo success at last
However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.
A subcutaneous answer to PD-1’s patent problem
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
